FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040496476> ?p ?o ?g. }

• W2040496476 endingPage "1667" @default.
• W2040496476 startingPage "1659" @default.
• W2040496476 abstract "BackgroundCilostazol reduces restenosis and repeat revascularization after endovascular therapy (EVT) in claudicant patients with femoropopliteal lesions. However, the efficacy of cilostazol in patients with critical limb ischemia (CLI) is unclear. Therefore, we investigated the effect of cilostazol on outcomes in patients with CLI.MethodsFrom January 2004 to December 2009, 618 patients (30.8% women, 356 treated with cilostazol, 72.4 ± 7.3 years old) with CLI underwent EVT for de novo infrainguinal lesions. Their data were retrospectively analyzed. The primary outcome measure was amputation-free survival (AFS), The secondary outcome measures were overall survival, limb salvage, freedom from repeat revascularization, and freedom from surgical conversion. Mean follow-up was 21 ± 14 months.ResultsAFS and the limb salvage rate at 5 years were significantly higher in the cilostazol-treated group (47.7% vs 32.7%, P < .01; 86.6% vs 75.3%, P < .01; respectively). However, overall survival and freedom from repeat revascularization at 5 years did not differ significantly between the two groups (43.9% vs 46.0%, P = .24; 39.9% vs 31.8%, P = .21, respectively). Freedom from surgical conversion at 5 years was significantly higher in the cilostazol-treated group (91.0% vs 81.2%, P < .01). After correcting all end points with baseline variables, cilostazol was effective for prevention of AFS (hazard ratio [HR], 0.67; 95% confidential interval [CI], 0.49-0.91; adjusted P = .01) and improvement of limb salvage rate (HR, 0.42; 95% CI, 0.25-0.69; adjusted P < .01). There was no significant difference in overall survival, repeat revascularization, and surgical conversion between the groups.ConclusionsCilostazol may improve AFS and limb salvage rate after EVT for infrainguinal disease in patients with CLI. Cilostazol reduces restenosis and repeat revascularization after endovascular therapy (EVT) in claudicant patients with femoropopliteal lesions. However, the efficacy of cilostazol in patients with critical limb ischemia (CLI) is unclear. Therefore, we investigated the effect of cilostazol on outcomes in patients with CLI. From January 2004 to December 2009, 618 patients (30.8% women, 356 treated with cilostazol, 72.4 ± 7.3 years old) with CLI underwent EVT for de novo infrainguinal lesions. Their data were retrospectively analyzed. The primary outcome measure was amputation-free survival (AFS), The secondary outcome measures were overall survival, limb salvage, freedom from repeat revascularization, and freedom from surgical conversion. Mean follow-up was 21 ± 14 months. AFS and the limb salvage rate at 5 years were significantly higher in the cilostazol-treated group (47.7% vs 32.7%, P < .01; 86.6% vs 75.3%, P < .01; respectively). However, overall survival and freedom from repeat revascularization at 5 years did not differ significantly between the two groups (43.9% vs 46.0%, P = .24; 39.9% vs 31.8%, P = .21, respectively). Freedom from surgical conversion at 5 years was significantly higher in the cilostazol-treated group (91.0% vs 81.2%, P < .01). After correcting all end points with baseline variables, cilostazol was effective for prevention of AFS (hazard ratio [HR], 0.67; 95% confidential interval [CI], 0.49-0.91; adjusted P = .01) and improvement of limb salvage rate (HR, 0.42; 95% CI, 0.25-0.69; adjusted P < .01). There was no significant difference in overall survival, repeat revascularization, and surgical conversion between the groups. Cilostazol may improve AFS and limb salvage rate after EVT for infrainguinal disease in patients with CLI." @default.
• W2040496476 created "2016-06-24" @default.
• W2040496476 creator A5003869519 @default.
• W2040496476 creator A5004193056 @default.
• W2040496476 creator A5011740789 @default.
• W2040496476 creator A5016016981 @default.
• W2040496476 creator A5016168216 @default.
• W2040496476 creator A5036945349 @default.
• W2040496476 creator A5046761848 @default.
• W2040496476 creator A5048656899 @default.
• W2040496476 date "2011-12-01" @default.
• W2040496476 modified "2023-10-01" @default.
• W2040496476 title "Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia" @default.
• W2040496476 cites W1970419820 @default.
• W2040496476 cites W1979817255 @default.
• W2040496476 cites W1985613228 @default.
• W2040496476 cites W1988719433 @default.
• W2040496476 cites W1996130660 @default.
• W2040496476 cites W2011976831 @default.
• W2040496476 cites W2026714731 @default.
• W2040496476 cites W2047644852 @default.
• W2040496476 cites W2048611935 @default.
• W2040496476 cites W2048745305 @default.
• W2040496476 cites W2053492914 @default.
• W2040496476 cites W2066283698 @default.
• W2040496476 cites W2067229002 @default.
• W2040496476 cites W2080278301 @default.
• W2040496476 cites W2118797814 @default.
• W2040496476 cites W2119380659 @default.
• W2040496476 cites W2135944336 @default.
• W2040496476 cites W2143102433 @default.
• W2040496476 cites W2144961144 @default.
• W2040496476 cites W2147826941 @default.
• W2040496476 cites W2168187685 @default.
• W2040496476 cites W2185467918 @default.
• W2040496476 cites W4236938366 @default.
• W2040496476 doi "https://doi.org/10.1016/j.jvs.2011.06.024" @default.
• W2040496476 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21872419" @default.
• W2040496476 hasPublicationYear "2011" @default.
• W2040496476 type Work @default.
• W2040496476 sameAs 2040496476 @default.
• W2040496476 citedByCount "40" @default.
• W2040496476 countsByYear W20404964762012 @default.
• W2040496476 countsByYear W20404964762013 @default.
• W2040496476 countsByYear W20404964762014 @default.
• W2040496476 countsByYear W20404964762015 @default.
• W2040496476 countsByYear W20404964762016 @default.
• W2040496476 countsByYear W20404964762017 @default.
• W2040496476 countsByYear W20404964762018 @default.
• W2040496476 countsByYear W20404964762019 @default.
• W2040496476 countsByYear W20404964762020 @default.
• W2040496476 countsByYear W20404964762021 @default.
• W2040496476 countsByYear W20404964762022 @default.
• W2040496476 crossrefType "journal-article" @default.
• W2040496476 hasAuthorship W2040496476A5003869519 @default.
• W2040496476 hasAuthorship W2040496476A5004193056 @default.
• W2040496476 hasAuthorship W2040496476A5011740789 @default.
• W2040496476 hasAuthorship W2040496476A5016016981 @default.
• W2040496476 hasAuthorship W2040496476A5016168216 @default.
• W2040496476 hasAuthorship W2040496476A5036945349 @default.
• W2040496476 hasAuthorship W2040496476A5046761848 @default.
• W2040496476 hasAuthorship W2040496476A5048656899 @default.
• W2040496476 hasBestOaLocation W20404964761 @default.
• W2040496476 hasConcept C126322002 @default.
• W2040496476 hasConcept C141071460 @default.
• W2040496476 hasConcept C164705383 @default.
• W2040496476 hasConcept C207103383 @default.
• W2040496476 hasConcept C2776204877 @default.
• W2040496476 hasConcept C2777628954 @default.
• W2040496476 hasConcept C2778283817 @default.
• W2040496476 hasConcept C2778583881 @default.
• W2040496476 hasConcept C2779464278 @default.
• W2040496476 hasConcept C2779820409 @default.
• W2040496476 hasConcept C2781099653 @default.
• W2040496476 hasConcept C44249647 @default.
• W2040496476 hasConcept C500558357 @default.
• W2040496476 hasConcept C71924100 @default.
• W2040496476 hasConceptScore W2040496476C126322002 @default.
• W2040496476 hasConceptScore W2040496476C141071460 @default.
• W2040496476 hasConceptScore W2040496476C164705383 @default.
• W2040496476 hasConceptScore W2040496476C207103383 @default.
• W2040496476 hasConceptScore W2040496476C2776204877 @default.
• W2040496476 hasConceptScore W2040496476C2777628954 @default.
• W2040496476 hasConceptScore W2040496476C2778283817 @default.
• W2040496476 hasConceptScore W2040496476C2778583881 @default.
• W2040496476 hasConceptScore W2040496476C2779464278 @default.
• W2040496476 hasConceptScore W2040496476C2779820409 @default.
• W2040496476 hasConceptScore W2040496476C2781099653 @default.
• W2040496476 hasConceptScore W2040496476C44249647 @default.
• W2040496476 hasConceptScore W2040496476C500558357 @default.
• W2040496476 hasConceptScore W2040496476C71924100 @default.
• W2040496476 hasIssue "6" @default.
• W2040496476 hasLocation W20404964761 @default.
• W2040496476 hasLocation W20404964762 @default.
• W2040496476 hasOpenAccess W2040496476 @default.
• W2040496476 hasPrimaryLocation W20404964761 @default.
• W2040496476 hasRelatedWork W1973309579 @default.
• W2040496476 hasRelatedWork W1979219809 @default.

• next